Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCY vs ATG for GVHD Prophylaxis in Unrelated Donor Transplantation
NCT05153226Phase 3Active, not recruiting
- Sponsor
- DKMS
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by DKMS. Started Mar 2022; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05153226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153226.